GLSI NASDAQ
Greenwich LifeSciences, Inc.
1W: +4.7%
1M: +9.0%
3M: +13.0%
YTD: +39.6%
1Y: +164.0%
3Y: +139.1%
5Y: -17.5%
$27.65
+0.46 (+1.69%)
Weekly Expected Move ±12.4%
$20
$24
$27
$31
$34
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (20)
$GLSI shows Less Than 1k Shares Available to Short
$GLSI shows Less Than 1k Shares Available to Short
What is HC Wainwright’s Forecast for GLSI FY2026 Earnings?
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
3 things to look out for on Monday
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy?
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX)
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT)
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
What's Going On With Greenwich LifeSciences Friday?
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date